CDK4 and neoplasm: Multiple PDX and cell-line xenograft studies validate the synergistic antitumor activity of combined PI3Kα and CDK4/6 inhibition; some models showed durable regressions while others exhibited tumor stasis, highlighting dependency on tumor genotype and treatment scheduling (52).